{"organizations": [], "uuid": "1d25857c36f50ccc40c2f8503a3fa809160826e1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.pharmamedtechbi.com", "main_image": "", "site_section": "http://feeds.feedburner.com/PharmaBiotechFinancing", "section_title": "Pharma/Biotech Financing From Elsevier Business Intelligence", "url": "https://www.pharmamedtechbi.com/deals/201530680?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "country": "IL", "title": "Series E brings in $38mm for Selecta", "performance_score": 0, "site": "pharmamedtechbi.com", "participants_count": 0, "title_full": "Series E brings in $38mm for Selecta", "spam_score": 0.0, "site_type": "news", "published": "2015-09-09T02:40:00.000+03:00", "replies_count": 0, "uuid": "1d25857c36f50ccc40c2f8503a3fa809160826e1"}, "author": "", "url": "https://www.pharmamedtechbi.com/deals/201530680?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "ord_in_thread": 0, "title": "Series E brings in $38mm for Selecta", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Series E brings in $38mm for Selecta Deal Date: Sep-01-2015 / Deal # 201530680 Executive Summary \nSelecta Biosciences Inc. (antigen-specific immunotherapeutics) raised $38mm via its oversubscribed Series E financing to returning shareholders OrbiMed, Polaris Partners, Flagship Ventures, NanoDimension, Rusnano, and Leukon Investments, and new backers Sanofi-Genzyme BioVentures, Ridgeback Capital Management, Osage Partners, AJU IB Investment, and Sphera Global Health Care Fund. The proceeds will help finish Phase I trials for its lead compound SEL212 for refractory and tophaceous gout, and move the candidate into Phase II next year. Some money will also fund preclinical pipeline development.", "external_links": [], "published": "2015-09-09T02:40:00.000+03:00", "crawled": "2015-09-09T18:17:59.353+03:00", "highlightTitle": ""}